Been digging into the surgical robotics space and there's an interesting dynamic playing out between two major medical device players that most retail investors probably aren't paying close attention to.

Intuitive Surgical basically owns this market right now with their da Vinci systems. They've got over 11,000 units installed globally and the adoption keeps accelerating - surgeries performed jumped 18% year over year. That's real demand, not just hype. But here's what's wild: only about a quarter of their revenue actually comes from selling new robots. The real money is in the recurring services and parts business that grows with each installation. It's basically a subscription model built into the hardware.

The catch? Intuitive's trading at a 64 P/E ratio. That's expensive for any stock, even a growth story.

Meanwhile, Medtronic - which is way more diversified as a medical device company - is sitting at a 26 P/E. They've got their own surgical robot called Hugo that got FDA approval late last year. It's not as mature as da Vinci yet, but it's catching up. And unlike Intuitive, Medtronic actually pays a dividend yielding 2.9% while they build out Hugo's installed base.

What catches my eye is that Medtronic has the financial muscle and the existing medical device infrastructure to compete here without betting everything on one product line. If Hugo gains traction over the next decade - and there's no reason to think it won't given their track record - you're looking at a company that could see meaningful valuation expansion while also collecting dividend checks along the way.

For someone thinking in decades rather than quarters, there's real optionality there. A 10k investment gets you both income and exposure to one of the fastest-growing segments in healthcare. Worth keeping on the radar if you're building a long-term portfolio.